A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis by Nishijima, Tomohiro F. et al.
A comparison of toxicity profiles between the lower and 
standard dose capecitabine in breast cancer: a systematic 
review and meta-analysis
Tomohiro F. Nishijima1,*, Maya Suzuki2, and Hyman B. Muss1
1UNC Lineberger Comprehensive Cancer Center,170 Manning Drive, CB# 7305 Chapel Hill NC 
27599, USA
2Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
Abstract
Purpose—Capecitabine 1,000 mg/m2 bid × 14 days every 21 days (14/21) has been reported to 
have similar efficacy but more favorable toxicity profile than the approved dosage of 1,250 mg/m2. 
However, a dose-toxicity relationship of capecitabine in breast cancer patients has not been fully 
elucidated. We performed a systematic review and meta-analysis to compare a safety profile 
between capecitabine starting dose of 1,000 and 1,250 mg/m2 bid.
Methods—Studies were identified using PubMed, ASCO and San Antonio Breast Cancer 
Symposium abstract databases through December 2015. Eligible trials included phase II/ III trials 
of capecitabine monotherapy at 1,000 or 1,250 mg/m2 bid (14/21) for breast cancer patients that 
reported adequate safety data for all (Grade 1-4) or high (Grade 3-4) grade hand foot syndrome 
(HFS), diarrhea, fatigue, nausea, vomiting, stomatitis, neutropenia, thrombocytopenia, or anemia, 
as well as dose reductions, treatment discontinuation or treatment-related deaths. The summary 
incidence was calculated using random- effects models.
Results—A total of 4,833 patients from 34 trials were included. 1,218 and 3,615 patients were 
treated with capecitabine 1,000 and 1,250 mg/m2 bid, respectively. A significantly lower incidence 
of dose reduction (15.9 vs. 39.0%; P = 0.007), high-grade HFS (12.0 vs. 19.0%; P = 0.01), 
diarrhea (5.3 vs. 9.1%; P = 0.01), and neutropenia (1.8 vs. 7.3%; P < 0.01) and all-grade 
neutropenia (5.8 vs. 25.4%; P = 0.01) was seen in capecitabine 1,000 mg/m2 compared to 1,250 
mg/m2.
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Conclusions—Capecitabine monotherapy at 1,000 mg/m2 bid (14/21) has a clinically 
meaningful and significantly better toxicity profile compared to 1,250 mg/m2 bid (14/21).
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Introduction
Capecitabine is an oral pro-drug that is converted to 5-fluorouracil (5-FU) via a three-step 
enzymatic process, the final step of which is mediated by thymidine phosphorylase. Given 
this enzyme is over expressed in tumor compared with normal tissue, 5-FU is preferentially 
generated within the tumor tissue, conferring relatively selective cytotoxicity to the tumor 
[1]. Capecitabine is one of the most active agents in metastatic breast cancer (MBC). The 
FDA has approved capecitabine monotherapy 1,250 mg/m2 twice daily (bid) on days 1–14 
followed by a 7-day rest period (14/21) for MBC that is resistant to both paclitaxel and 
anthracyclines [2]. It has also been extensively studied in both pretreated and previously 
untreated MBC patients and demonstrated efficacy in response rate and progression-free 
survival (PFS) [3,4] .However, 26%–65% of patients had their dose reduced by at least 20% 
in these trials [5,6]. The main treatment-limiting toxicities at this dosage were hand-and-foot 
syndrome (HFS; also called palmer-plantar erythrodysesthesia) and diarrhea. Based on this 
experience, a number of investigators have evaluated capecitabine at a lower starting dose 
(1,000 mg/m2 bid) and demonstrated similar efficacy to the approved dose and a more 
favorable side effect profile with an incidence of dose reduction, ranging from 16 to 34% in 
phase II trials [7,8]. However, there has been a substantial variation in the incidence of 
toxicities among clinical trials and there has been no systematic attempt to synthesize these 
data in order to define the overall risk of toxicities induced by the lower and standard dose 
capecitabine. Therefore, we conducted a systematic review and meta-analysis of available 
clinical trials to compare a safety profile between capecitabine starting dose of 1,000 and 1, 
250 mg/m2 bid in breast cancer patients.
Methods
Data source
This analysis was performed in accordance with the preferred reporting items for systematic 
reviews and meta-analyses (PRISMA) statement [9]. We conducted an independent review 
of PubMed from January 1966 to December 2015. Searches were performed by using the 
keywords “capecitabine” and “breast cancer” and were limited to clinical trials. We searched 
abstracts and virtual meeting presentations utilizing the same search terms from the 
American society of clinical oncology (ASCO) conference and San Antonio breast cancer 
symposiums (SABCS) through December 2015 to identify relevant studies. An independent 
search of the web of science, Embase, and Cochrane electronic databases was also 
performed to ensure that no additional studies were overlooked. In cases of duplicate 
publications, only the most complete, recent, and updated report of the study was included.
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Study selection
Clinical trials that met the following criteria were included: (1) phase II and III trials of 
capecitabine monotherapy at 1,000 or 1,250 mg/m2 bid on day 1 through 14 every 3 weeks 
for breast cancer patients; and (2) reporting events or event rate and sample size for any all 
(grade 1-4) or high (grade 3-4) grade adverse events (AEs), individual, all or high grade 
AEs, dose reductions, treatment discontinuation or treatment-related deaths. We assessed 
nine individual AEs which were commonly reported in clinical trials. They included hand 
foot syndrome (HFS), diarrhea, fatigue, nausea, vomiting, stomatitis, neutropenia, anemia 
and thrombocytopenia. We did not include trials of capecitabine combined with other agents. 
Independent reviewers (TFN and MS) screened reports that included the key terms by their 
titles and abstracts for relevance. Then, full texts of the relevant articles were retrieved to 
assess eligibility. The references of relevant reports were also reviewed manually.
Data extraction
Two investigators (TFN and MS) independently performed data extraction. The following 
information was recorded for each study: first author's name, year of publication, trial phase, 
age, disease stage, treatment setting, capecitabine dose, number of patients available for 
analysis, number of cycles of capecitabine, CTCAE version, and number of the following 
adverse events: any, all, or high grade AEs, individual, all or high grade AEs (HFS, diarrhea, 
fatigue, nausea, vomiting, stomatitis, neutropenia, anemia and thrombocytopenia), dose 
reductions, treatment discontinuation and treatment-related deaths. Any discrepancies 
between reviewers were resolved by consensus. The number of patients evaluable for 
toxicity was utilized as the number analyzed for each trial, unless this was not indicated in 
the publication, in which case, the number of patients enrolled was utilized. In selected 
clinical trials, the adverse events were recorded according to the CTCAE.
Statistical analysis
The principal summary measures were incidence and corresponding 95 % confidence 
intervals (CIs) of the following AEs: any, all, or high grade AEs, individual, all or high grade 
AEs (HFS, diarrhea, fatigue, nausea, vomiting, stomatitis, neutropenia, thrombocytopenia, 
and anemia), dose reductions, treatment discontinuation and treatment-related deaths. The 
proportion of patients with those adverse outcomes and 95 % CIs were derived from each 
trial. Statistical heterogeneity in results between trials included in the meta-analysis was 
examined using Cochrane's Q statistic, and inconsistency was quantified with I2 statistic 
[100 % × (Q - df)/Q], which estimates the percentage of total variation across studies due to 
heterogeneity rather than chance [10]. The assumption of homogeneity was considered 
invalid for P values less than 0.10. We used a random-effects model to produce a pooled 
overall estimate for incidence of the adverse outcomes. Differences in the incidences 
between the two groups were assessed using Q statistics. We evaluated publication bias 
using funnel plots and with the Begg and Egger tests [11,12]. A two tailed P value of less 
than 0.05 was considered statistically significant. Statistical analyses were performed by 
using the comprehensive meta-analysis program (Version 2, Biostat, Englewood, NJ, USA).
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Results
Search results and population characteristics
Our search strategy yielded 391 potentially relevant publications. 360 citations were 
excluded. This large proportion of studies that had to be excluded from analyses consisted of 
reviews, observational studies, non-capecitabine trials, non-breast cancer trials and trials of 
capecitabine combined with other therapy This selection process and reasons for study 
exclusion are shown in a flow diagram (Fig. 1). We found additional reports identified 
through manual review of the references of included publications and ASCO and SABCS 
abstract database [7,13,14]. Thus, a total of 34 trials with 4,833 patients were considered 
eligible for the meta-analysis, including 12 phase III trials and 22 phase II trials. 30 trials 
were in the locally advanced or MBC setting, two trials were in the neoadjuvant setting, and 
two trials were in the adjuvant setting. 1,218 patients from 13 trials and 3,615 patients from 
23 trials were treated with capecitabine starting dose at 1,000 and 1,250 mg/m2 bid, 
respectively. There were two trials which modified the capecitabine starting dose from 1,250 
to 1,000 mg/m2 bid. These trials reported toxicity outcomes according to the capecitabine 
starting dose [15,16]. We did not include a trial which administered capecitabine 1,250 
mg/m2 bid in patients ≤ 65 years and 1,000 mg/m2 bid in patients > 65 years and did not 
report toxicity outcomes separately for the two dosing groups [17]. There were differences 
in the number of trials included for each endpoint because the study endpoints of interest 
were not consistently reported in all trials.
Comparison of toxicity profiles (Toxicity profile)
Toxicity data for high grade HFS were available for 33 trials. The incidence of high grade 
HFS in patients receiving capecitabine 1,000 mg/m2 bid and 1,250 mg/m2 bid was 
respectively 12.0% (95% CI, 9.0-15.7%) and 19.0% (95% CI, 15.2-23.4%) by using the 
random-effects model (Table 2). The test for heterogeneity was significant in the lower (Q = 
17.5; P = 0.06; I2 = 42.9) and approved (Q = 149.0; P < 0.001; I2 = 85.9) dose groups. 
There was a significant decrease in the incidence of high grade HFS with the use of the 
lower dose compared with the standard dose (P = 0.01). High grade diarrhea developed less 
frequently in patients treated with the lower dose of capecitabine than those treated with the 
approved dose (5.3 vs. 9.1%; P = 0.011). There were fewer all-grade neutropenia events 
among patients treated with capecitabine 1,000 mg/m2 bid (5.8%) than among patients 
treated with 1,250 mg/m2 bid (25.4%). A lower incidence of high-grade neutropenia was 
also observed in capecitabine 1,000 mg/m2 bid group (1.8%) in comparison with 1,250 
mg/m2 bid group (7.3%). Patients treated with capecitabine 1,000 mg/m2 bid required a 
dose reduction for toxicity less frequently than those treated with 1,250 mg/m2 bid (P = 
0.007). The incidence of dose reduction with the lower and approved dose capecitabine was 
respectively 15.9% (95% CI, 7.5-30.5%) and 39.0% (95% CI, 32.4-45.9%). There was also a 
trend toward lower incidence of high-grade vomiting (P = 0.05) and high-grade anemia (P = 
0.08) in the capecitabine 1,000 mg/m2 bid group compared with the 1,250 mg/m2 bid group. 
There was no significant difference in the incidence of treatment discontinuation and 
treatment-related deaths between the two groups.
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Publication bias
We found no evidence of publication bias for incidence of any all- and high-grade AEs, all- 
and high grade HFS, fatigue, vomiting, and stomatitis and all-grade diarrhea, nausea and 
anemia and dose reductions, treatment discontinuation and treatment-related deaths. The 
Egger test suggested some evidence of publication bias (P < 0.05) for incidence of all- and 
high-grade neutropenia and thrombocytopenia and high-grade diarrhea, nausea, and anemia. 
However, the Begg tests showed no evidence of bias for the incidence of these outcomes (P 
> 0.05). This difference in the results obtained from the two methods may be due to a greater 
statistical power of the Egger test [44].
Discussion
A goal of the current analysis was to systematically assess the overall risk of toxicities 
associated with the lower and standard dose capecitabine. Our meta-analysis of 34 clinical 
trials demonstrated a dose-toxicity relationship of capecitabine in breast cancer patients. A 
significantly lower incidence of dose reductions, high grade HFS, diarrhea, neutropenia and 
all grade neutropenia was observed in capecitabine starting dose of 1,000 mg/m2 bid 
compared to 1,250 mg/m2 bid. These findings reinforce the results of the previous 
retrospective study performed by Hennessy et al. at M. D. Anderson Cancer Center [45]. In 
their study, 106 patients receiving capecitabine monotherapy who were evaluable for toxicity 
were grouped according to the starting dose of capecitabine: A= 1250 ± 5% mg/m2 bid (n = 
51); B = 1125 ± 5% mg/m2 bid. (n = 16); C ≤ 1000 +5% mg/m2 bid (n = 39). Although no 
statistical comparison was performed, the incidence of dose reduction (28 vs. 41%), high 
grade HFS (20 vs. 33%), and diarrhea (3 vs. 13%) was numerically lower in the group C 
compared with group A. Overall it showed a trend to a better tolerability with the lower dose 
of capecitabine. In addition to the milder toxicity profile, clinical trials have shown that a 
lower starting capecitabine dose is comparable in efficacy to the approved dose despite the 
lack of a randomized trial comparing the two approaches. Randomized phase II/III clinical 
trials of first-line capecitabine (1,250 mg/m2 bid (14/21)) in MBC patients showed a median 
time to progression (TTP) of 4.1-7.1 months and a median OS of 19.6-29.4 months [19, 46]. 
Findings from phase III trials of first-line capecitabine (1,000 mg/m2 bid (14/21)) in MBC 
patients are similar to the results of the approved dose capecitabine. The median PFS and 
TTP were in the range of 5.7–6.0 months and the median OS was within the range of 21.2–
24.0 months [34,35]. Because of the substantial heterogeneity in the trial settings including 
treatment intent (curative vs. palliative) and line of therapy, we did not perform a meta-
analysis of the trials to compare the efficacy of capecitabine starting dose of 1,250 to 1,000 
mg/m2 bid.
These data coupled with clinical experience and the palliative goal of treatment in MBC 
have led many clinicians to start their MBC patients on a lower starting dose of capecitabine 
than the 1,000 mg/m2 bid dose, whether as first-line treatment or later in the course of 
therapy. Ambros and colleagues commonly prescribe capecitabine in their MBC population 
at a fixed dose of 1000mg bid for 14 of every 21 days within their single large breast-
specific oncology group [47]. Given the lack of published data on this dose, they 
retrospectively analyzed data from 86 patients treated with this regimen (CAPE-L) 
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regardless of the number of prior therapy lines. The median starting dose was 633.5mg/m2 
(range: 303.4–965.3) bid, roughly 50% of the FDA approved dose. They compared 
outcomes in this population to a historical control group based on literature review of 12 
studies incorporating the approved dose and schedule of capecitabine. Overall response rate 
and median TTP was similar between the CAPE-L and the standard dose cohorts (24.3 vs. 
24 %), and (7 months, 95 % CI 5.5-8.5 vs. 5.1 months, 95 % CI 4.5-5.7, respectively). 
Median OS was longer in the CAPE-L cohort (24 months, 95 % CI 16.8-31.2) versus (12.1 
months, 95 % CI 9.6-14.4), however, this was attributed by the investigators to the higher 
percentage of patients in the CAPE-L group receiving capecitabine as first-line 
chemotherapy and harboring endocrine positive disease. They observed a lower incidence of 
grade 3–4 HFS (5.8 vs. 11.4 %) and diarrhea (4.7 vs. 10.2 %) with CAPE-L compared to the 
historical control group. Bertelsen et al. also performed a retrospective analysis of 84 
patients treated with a low dosage of capecitabine monotherapy as their first, second, or third 
line of chemotherapy for metastatic or unresectable locally advanced breast cancer [48]. 
Eighty-six percent of the patients received a flat dosage of 1000 mg bid and the median 
starting dosage was 565mg/m2 bid, with a range of 305 to 1057 mg/m2. The median PFS for 
patients with measurable disease was 4.1 months (95 % CI 2.9-5.7) which was similar to the 
median PFS values 4.2-4.4 months for capecitabine monotherapy reported in the randomized 
trials with similar eligibility criteria [30,31]. Although the authors did not report detailed 
toxicity outcomes, they stated that the low dose of capecitabine was well tolerated and only 
2 patients discontinued capecitabine due to toxicity. In addition to the approach of lowering 
the starting capecitabine dose, alternative schedules have been investigated to improve 
treatment tolerability. Continuous metronomic capecitabine monotherapy has been tested in 
two phase II trials in patients with advanced breast cancer. Capecitabine was given 
continuously at 666 mg/m2 bid in Harvey's trial and at fixed dose 1500 mg once a day in 
Fedele's trial [49,50]. Overall response rate and median TTP/PFS was 36% and 3.1 months 
in Harvey's trial and 24% and 7 months in Fedele's trial, respectively. The most common 
grade 3-4 AE was hand foot syndrome (5-17%) and in general these regimens were well 
tolerated. In Japan, an intermittent 4-week schedule (828 mg/m2 bid, days 1–21 every 28 
days) has been studied in phase II trials of advanced breast cancer [51-53]. In the trials, 
overall response rate and median TTP/PFS was 18%-46% and 5.1-7.2 months, respectively. 
These results are comparable to those with the standard 3-weekly intermittent schedule. An 
incidence of hand–foot syndrome (15-18%) was similar to the 3-weekly regimen, but high 
grade diarrhea was seen in only one patient in these trials. Notably, a 7-days-on, 7-days-off 
(7/7) regimen of capecitabine was developed by Traina et al. based on the Norton–Simon 
mathematical model [54]. In their phase I trial, the most frequently grade 2-3 AEs were 
hand-foot syndrome (29%), leukopenia/neutropenia (24%), and fatigue (19%). The 
maximum-tolerated doses of capecitabine was 2,000 mg bid. Although capecitabine 
monotherapy on this 7/7 schedule has not been evaluated in larger clinical trials, this dosing 
schedule is commonly used in the U.S. because of its good tolerability seen in daily practice.
As treatment for metastatic breast cancer is palliative, minimizing toxicity and loss of 
function associated with treatment is of major importance. Improvement in chemotherapy 
tolerability without compromising efficacy is of particular importance in older adults with 
MBC. Elderly cancer patients are known to be at higher risk of chemotherapy-related 
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adverse events [55,56]. In a pooled analysis of five phase II/III trials of capecitabine 1,250 
mg/m2/day bid (14/21), an incidence of treatment discontinuation due to toxicity was higher 
in women >65 years (24.4%) compared with younger women (13.0-15.0%) [3]. 
Additionally, treatment related mortality was observed in a phase 2 study of capecitabine 
monotherapy in the older (≥ 65 years) adults with MBC [15]. In this trial two of 30 patients 
treated with capecitabine starting dose of 1250mg/m2 bid and one of 43 patients treated with 
a lower starting dose (1000 mg/m2) died due to toxicities. Given these findings, a 
prospective study of low dose capecitabine monotherapy (e.g. fixed-dose 1,000 mg bid, 2 
weeks on and 1 week off) in this population may be indicated in order to not only better 
assess the survival outcomes but also toxicity and outcomes particularly important for the 
elderly such as the maintenance of independent physical and social function, and quality of 
life.
Our study had several limitations. First, significant heterogeneity was observed in the 
incidence analyses although we included only phase II and III trials of breast cancer patients. 
This may be related to the differences in treatment intent, line of therapy, prior treatments 
and sample size. We conducted all analyses using the random-effects model to take into 
account the between-study variation. Second, this is a meta-analysis at study level; therefore 
variables at the patient level were not incorporated into the analysis. Thus we could not 
establish risk factors associated with the development of toxicities. Third, as with any meta-
analysis, the results described here are affected by the limitations of individual clinical trials 
that were selected for this meta-analysis.
In conclusion, our meta-analysis showed that capecitabine monotherapy at 1,000 mg/m2 bid 
for 14 days every 21 days has a clinically meaningful and significantly better toxicity profile 
in patients with breast cancer compared to the approved dose of capecitabine at 1,250 
mg/m2 bid. Given our finding and the efficacy results from the clinical trials, capecitabine 
monotherapy at 1,000 mg/m2 bid for 14 days every 21 days is a reasonable standard of care. 
Prospective studies are warranted to determine whether further lower doses of capecitabine 
or other doses and schedules can achieve improvement in tolerability without compromising 
efficacy in patients with advanced breast cancer.
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Figure 1. Flow diagram; selection process for the trials
Abbreviations: ASCO, American Society of Clinical Oncology; SABCS, San Antonio 
Breast Cancer Symposium
Nishijima et al. Page 12
Breast Cancer Res Treat. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Nishijima et al. Page 13
Ta
bl
e 
1
C
ha
ra
ct
er
ist
ic
s o
f t
he
 tr
ia
ls 
in
cl
ud
ed
 in
 th
e m
et
a-
an
al
ys
is
Au
th
or
, 
Ye
a
r
Ph
as
e
A
ge
 (y
ea
rs
) m
ed
ian
 
(ra
ng
e)
D
ise
as
e 
st
ag
e
Tr
ea
tm
en
t s
et
tin
g
C
ap
ec
ita
bi
ne
 d
os
e
N
o.
 o
f p
at
ie
nt
s 
fo
r 
a
n
a
ly
sis
N
um
be
r o
f c
yc
le
s 
m
ed
ia
n 
(ra
ng
e)
C
TC
A
E 
ve
rs
io
n
B
lu
m
, 1
99
91
8
II
56
 (2
6-7
8)
M
et
as
ta
tic
2n
d 
or
 3
rd
 li
ne
1,
25
5 
m
g/
m
2 
bi
d
16
2
N
R
1
O
sh
au
gh
ne
ss
y, 
20
01
19
II
 R
CT
69
 (5
4-8
3)
Lo
ca
lly
 a
dv
an
ce
d/
 M
et
as
ta
tic
1s
t l
in
e
1,
25
5 
m
g/
m
2 
bi
d
61
4
1
B
lu
m
, 2
00
12
0
II
53
 (2
9–
77
)
Lo
ca
lly
 a
dv
an
ce
d/
 M
et
as
ta
tic
2n
d 
or
 la
te
r l
in
e
1,
25
5 
m
g/
m
2 
bi
d
74
N
R
1
Ja
ko
b,
 2
00
22
1
II
46
 (3
5-6
0)
M
et
as
ta
tic
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
14
5 
(1–
19
)
1
Ta
lb
ot
, 2
00
22
2
II
 R
CT
52
 (3
3-6
7)
Lo
ca
lly
 a
dv
an
ce
d/
 M
et
as
ta
tic
1s
t, 
2n
d 
or
 3
rd
 li
ne
1,
25
5 
m
g/
m
2 
bi
d
22
N
R
N
R
R
ei
ch
ar
dt
, 2
00
32
3
II
56
 (3
2–
77
)
M
et
as
ta
tic
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
13
6
4 
(1–
33
)
N
R
Fu
m
ol
ea
u,
 2
00
42
4
II
54
 (3
0–
80
)
Lo
ca
lly
 a
dv
an
ce
d/
 M
et
as
ta
tic
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
12
6
6 
(1–
15
)
N
R
W
ist
, 2
00
42
5
II
55
 (3
5-7
4)
Lo
ca
lly
 a
dv
an
ce
d/
 M
et
as
ta
tic
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
48
N
R
1
Le
e,
 2
00
42
6
II
48
 (3
1–
66
)
M
et
as
ta
tic
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
38
6 
(1–
15
)
2
M
ill
er
,
 
20
05
6
II
I
52
 (3
0-7
7)
M
et
as
ta
tic
1s
t, 
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
21
5
N
R
2
B
aje
tta
, 2
00
51
5
II
73
 (6
5-8
9)
M
et
as
ta
tic
1s
t o
r 2
nd
 li
ne
1,
25
0 
m
g/
m
2 
bi
d
30
6 
(1-
8)
N
R
1,
00
0 
m
g/
m
2 
bi
d
43
6 
(1-
8)
El
-H
el
w
,
 
20
05
7
II
48
 (2
0–
73
)
M
et
as
ta
tic
1s
t, 
2n
d 
or
 la
te
r l
in
e
1,
00
0 
m
g/
m
2 
bi
d
57
4 
(1-
44
)
N
R
Ca
m
er
on
, 2
00
82
7
II
51
 (2
8–
83
)
Lo
ca
lly
 a
dv
an
ce
d/
 M
et
as
ta
tic
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
19
1
N
R
3
R
os
si,
 2
00
71
6
II
62
 (3
8-8
7)
M
et
as
ta
tic
1s
t, 
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
7
9 
(1-
35
)
N
R
1,
00
0 
m
g/
m
2 
bi
d
30
v
o
n
 M
in
ck
w
itz
, 2
00
92
8
II
I
59
 (3
3-8
2)
Lo
ca
lly
 a
dv
an
ce
d/
 M
et
as
ta
tic
1s
t o
r 2
nd
 li
ne
1,
25
0 
m
g/
m
2 
bi
d
78
6 
(1-
42
)
2
M
us
s, 
20
09
29
II
I
>
=
65
St
ag
e 
I t
o 
III
B
A
dju
va
n
t
1,
00
0 
m
g/
m
2 
bi
d
29
9
6
3
H
or
to
ba
gy
i, 
20
10
30
II
I
52
 (2
5–
79
)
Lo
ca
lly
 a
dv
an
ce
d/
 M
et
as
ta
tic
1s
t, 
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
36
8
4 
(1-
33
)
3
Sp
ar
an
o,
 2
01
03
1
II
I
53
 (2
4-8
1)
M
et
as
ta
tic
1s
t, 
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
60
3
5 
(1-
50
)
3
K
au
fm
an
n,
 2
01
03
2
II
65
 (3
7–
90
)
M
et
as
ta
tic
1s
t l
in
e
1,
00
0 
m
g/
m
2 
bi
d
16
1
7
2
Cl
em
on
s, 
20
10
33
II
 R
CT
54
 (3
1-7
4)
M
et
as
ta
tic
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
43
3 
(1-
19
)
3
R
ob
er
t, 
20
11
34
II
I
57
 (2
3-8
8)
M
et
as
ta
tic
1s
t l
in
e
1,
00
0 
m
g/
m
2 
bi
d
20
1
9
N
R
Pa
lli
s, 
20
12
5
II
I
60
 (3
4–
82
)
M
et
as
ta
tic
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
74
6 
(1–
15
)
3
St
oc
kl
er
,
 
20
11
35
II
I
62
Lo
ca
lly
 a
dv
an
ce
d/
 M
et
as
ta
tic
1s
t l
in
e
1,
00
0 
m
g/
m
2 
bi
d
10
7
12
2
B
as
el
ga
, 
20
12
8
II
 R
CT
54
Lo
ca
lly
 a
dv
an
ce
d/
 M
et
as
ta
tic
1s
t o
r 2
nd
 li
ne
1,
00
0 
m
g/
m
2 
bi
d
11
2
7
3
H
ua
ng
, 2
01
23
6
II
50
 (2
6–
71
)
M
et
as
ta
tic
1s
t, 
2n
d 
or
 la
te
r l
in
e
1,
00
0 
m
g/
m
2 
bi
d
64
4 
(1–
20
)
3
G
ol
ds
te
in
, 2
01
31
3
II
 R
CT
57
 (3
1-8
0)
M
et
as
ta
tic
1s
t l
in
e
1,
00
0 
m
g/
m
2 
bi
d
66
7
N
R
Breast Cancer Res Treat. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Nishijima et al. Page 14
Au
th
or
, 
Ye
a
r
Ph
as
e
A
ge
 (y
ea
rs
) m
ed
ian
 
(ra
ng
e)
D
ise
as
e 
st
ag
e
Tr
ea
tm
en
t s
et
tin
g
C
ap
ec
ita
bi
ne
 d
os
e
N
o.
 o
f p
at
ie
nt
s 
fo
r 
a
n
a
ly
sis
N
um
be
r o
f c
yc
le
s 
m
ed
ia
n 
(ra
ng
e)
C
TC
A
E 
ve
rs
io
n
Cr
ow
n
, 
20
13
37
II
I
54
 (3
1-7
7)
M
et
as
ta
tic
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
21
5
6 
(1-
47
)
3
A
ro
w
o
lo
, 2
01
33
8
II
50
 (3
2–
70
)
Lo
ca
lly
 a
dv
an
ce
d
N
eo
ad
juv
an
t
1,
00
0 
m
g/
m
2 
bi
d
16
(3-
8)
2
To
la
ne
y,
 
20
14
39
II
53
 (2
9–
71
)
Ea
rly
 st
ag
e 
op
er
ab
le
N
eo
ad
juv
an
t
1,
00
0 
m
g/
m
2 
bi
d
24
4
N
R
M
ita
, 2
01
44
0
II
 R
CT
54
 (3
9-6
9)
Lo
ca
lly
 a
dv
an
ce
d/
 M
et
as
ta
tic
2n
d 
lin
e
1,
25
0 
m
g/
m
2 
bi
d
14
N
R
3
Sm
or
en
bu
rg
, 2
01
44
1
II
I
75
 (6
5–
86
)
M
et
as
ta
tic
1s
t l
in
e
1,
00
0 
m
g/
m
2 
bi
d
38
7 
(1–
8)
3
K
au
fm
an
, 2
01
54
2
II
I
53
 (2
6-8
0)
Lo
ca
lly
 a
dv
an
ce
d/
 M
et
as
ta
tic
1s
t, 
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
54
6
5 
(1-
61
)
3
M
ar
tín
, 2
01
54
3
II
 R
CT
61
 (3
4–
87
)
M
et
as
ta
tic
1s
t, 
2n
d 
or
 la
te
r l
in
e
1,
25
0 
m
g/
m
2 
bi
d
95
N
R
N
R
Le
e,
 2
01
51
4
II
I
48
St
ag
e 
I t
o 
III
B
A
dju
va
n
t
1,
25
0 
m
g/
m
2 
bi
d
45
5
N
R
N
R
A
bb
re
v
ia
tio
ns
: C
TC
A
E,
 C
om
m
on
 T
er
m
in
ol
og
y 
Cr
ite
ria
 fo
r A
dv
er
se
 E
ve
n
ts
; N
R,
 n
ot
 re
po
rte
d;
 R
CT
,
 
R
an
do
m
iz
ed
 C
on
tro
lle
d 
Tr
ia
l
Breast Cancer Res Treat. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Nishijima et al. Page 15
Ta
bl
e 
2
In
ci
de
nc
e 
of
 to
xi
ci
tie
s, 
in
cl
ud
in
g 
95
%
 C
I f
ro
m
 th
e 
ra
nd
om
 e
ffe
ct
s m
od
el
 a
nd
 n
um
be
r 
of
 tr
ia
ls 
in
 e
ac
h 
gr
o
u
p
C
ap
ec
ita
bi
ne
 1
,0
00
 m
g/
m
2 
bi
d
C
ap
ec
ita
bi
ne
 1
,2
50
 m
g/
m
2 
bi
d
N
o.
 o
f t
ri
al
s
In
ci
de
nc
e 
%
95
%
 C
I
N
o.
 o
f t
ri
al
s
In
ci
de
nc
e 
%
95
%
 C
I
P 
va
lu
e
N
on
-h
em
at
ol
og
ic
al
 A
Es
A
ll-
gr
ad
e 
H
FS
8
52
.8
40
.4
-6
4.
9
20
52
.4
46
.4
-5
8.
4
0.
95
1
H
ig
h-
gr
ad
e 
H
FS
11
12
.0
9.
0-
15
.7
22
19
.0
15
.2
-2
3.
4
0.
01
0
A
ll-
gr
ad
e 
D
ia
rrh
ea
8
32
.7
22
.1
-4
5.
4
18
36
.7
31
.6
-4
2.
1
0.
55
1
H
ig
h-
gr
ad
e 
D
ia
rrh
ea
9
5.
3
3.
9-
7.
0
20
9.
1
6.
7-
12
.3
0.
01
1
A
ll-
gr
ad
e 
Fa
tig
ue
7
35
.9
22
.4
-5
2.
0
17
25
.8
21
.7
-3
0.
3
0.
18
3
H
ig
h-
gr
ad
e 
Fa
tig
ue
10
5.
1
3.
1-
8.
2
18
4.
5
2.
7-
7.
6
0.
74
3
A
ll-
gr
ad
e 
N
au
se
a
7
35
.8
22
.8
-5
1.
3
18
38
.1
32
.2
-4
4.
3
0.
78
4
H
ig
h-
gr
ad
e 
N
au
se
a
8
2.
9
1.
7-
4.
8
18
3.
7
1.
9-
7.
3
0.
54
1
A
ll-
gr
ad
e 
Vo
m
iti
ng
6
17
.9
9.
8-
30
.3
17
23
.0
19
.4
-2
7.
0
0.
39
3
H
ig
h-
gr
ad
e 
Vo
m
iti
ng
7
1.
8
1.
0-
3.
1
18
3.
8
2.
3-
6.
4
0.
05
0
A
ll-
gr
ad
e 
St
om
at
iti
s
6
18
.6
12
.3
-2
7.
0
15
15
.3
11
.5
-2
0.
1
0.
43
7
H
ig
h-
gr
ad
e 
St
om
at
iti
s
8
1.
9
1.
1-
3.
2
13
2.
2
1.
3-
3.
7
0.
65
9
H
em
at
ol
og
ic
al
 A
Es
A
ll-
gr
ad
e 
N
eu
tro
pe
ni
a
5
5.
8
1.
8-
17
.5
10
25
.4
17
.3
-3
5.
7
0.
01
1
H
ig
h-
gr
ad
e 
N
eu
tro
pe
ni
a
9
1.
8
1.
1-
2.
9
18
7.
3
5.
8-
9.
1
<
 0
.0
01
A
ll-
gr
ad
e 
A
ne
m
ia
3
28
.5
12
.6
-5
2.
6
11
29
.3
15
.5
-4
8.
4
0.
95
4
H
ig
h-
gr
ad
e 
A
ne
m
ia
5
1.
9
1.
0-
3.
5
15
3.
4
2.
7-
4.
2
0.
08
4
A
ll-
gr
ad
e 
Th
ro
m
bo
cy
to
pe
ni
a
4
8.
5
2.
2-
27
.9
10
13
.9
8.
0-
22
.8
0.
49
1
H
ig
h-
gr
ad
e 
Th
ro
m
bo
cy
to
pe
ni
a
6
2.
4
1.
0-
5.
3
16
2.
6
2.
0-
3.
4
0.
80
6
A
ny
 a
ll-
gr
ad
e 
A
Es
2
81
.1
2.
4-
99
.9
6
92
.7
87
.8
-9
5.
7
0.
68
1
A
ny
 h
ig
h-
gr
ad
e 
A
Es
6
27
.8
19
.9
-3
7.
4
7
40
.4
28
.4
-5
3.
7
0.
10
9
D
os
e 
R
ed
uc
tio
ns
5
15
.9
7.
5-
30
.5
14
39
.0
32
.4
-4
5.
9
0.
00
7
Tr
ea
tm
en
t D
isc
on
tin
ua
tio
n
9
11
.6
8.
8-
15
.3
18
10
.6
8.
5-
13
.2
0.
60
3
Tr
ea
tm
en
t-
re
la
te
d 
D
ea
th
s
13
1.
6
1.
0-
2.
5
21
1.
3
0.
8-
2.
1
0.
26
9
A
bb
re
v
ia
tio
ns
: A
Es
, a
dv
er
se
 e
v
en
ts
; H
FS
, h
an
d 
fo
ot
 sy
nd
ro
m
e
Breast Cancer Res Treat. Author manuscript; available in PMC 2017 April 01.
